Krasimir Marinov

The first step in the successful implementation of the National Plan for Cardiovascular Health is the education of children and adolescents on proper nutrition and physical activity. A pioneer in the implementation of this philosophy is the Municipality of Troyan, through the implementation of the municipal program for nutrition and mass sports for children and students.

The successful use of bromhexine hydrochloride (BRH) for COVID-19 prevention led us to apply the same method for flu prevention. The goal of this study is to observe whether BRH could protect people against influenza.This is non-interventional, observational, questionnaire-based survey. General practitioners informed their patients to take BRH 8 mg twice per day for at least 3 weeks if they want. The mean participant age was 58.9 years (95% CI: 57.4–60.5), with a median of 62 years, indicating that the sample predominantly consisted of individuals over 60 years of age.The average number of comorbidities was 0.98, and the mean duration of prophylactic use was 80 days (95% CI: 76.7–83.7). The reported influenza incidence within the sample was 10.6%.Influenza incidence among individuals taking BRH prophylactically was significantly lower compared to national data (36.15%). Longer use was associated with a modest reduction in risk. The number of comorbidities remained the strongest predictor of influenza occurrence. Age had no significant impact among those using BRH prophylactically. The model demonstrated good discriminative ability but limited calibration, and the results should be interpreted cautiously.

Colchicine has an excellent basis for being effective against COVID-19 due to its anti-inflammatory, immunomodulatory, cardioprotective effects, and prevention of microvascular thrombosis. In addition colchicine has also antiviral effect, extremely favorable safety profile and since it does not exert any overt immunosuppressive activity, does not interfere with the effective viral clearing nor is associated with the occurrence of secondary infections.However, all studies to date on the effects of colchicine with low doses for COVID-19 treatment are conflicting and rather disappointing.As colchicine has the remarkable ability to accumulate intensively in leukocytes, where the cytokine storm is generated, we started high, but save doses colchicine for COVID-19 patient treatment. Our assumption was that a safe increase in colchicine doses to reach micromolar concentrations in leukocytes will result in NLRP3 inflammasome/cytokine storm inhibition and will enhance its antiviral effect by inducing microtubule dissociation.Outpatients’ high-dose colchicine treatment practically prevents hospitalizations. The total colchicine uptake analysis demonstrates reverse relationship with hospitalization. The period of colchicine uptake analysis demonstrates reverse relationship with hospitalization and post-COVID-19 symptomatics. Unlike the WHO-recommended antiviral preparations molnupiravir, remdesivir and paxlovid, colchicine, in addition to its antiviral effect, prevents the cytokine storm, and therefore has a strong effect not only in outpatients, but also in inpatients. Unlike antivirals, colchicine significantly reduces post-COVID-19 symptoms. The side effects of colchicine are similar to those of paxlovide. Colchicine price is incomparably lower and it is also easily available.

In a series of publications, we attempt to demonstrate the prophylactic role of bromhexine hydrochloride (BHH) and the curative role of high colchicine doses against COVID-19. Effects of long-term prophylaxis with BHH are presented in two cases of elderly women with severe comorbidity. After long-term prophylactic use of BHH from 3 to 6 months, one does not get sick from COVID-19, and the other passes it almost asymptomatically, even though all their family members fall ill. The dramatic healing effect of colchicine was demonstrated in a family in which both spouses became ill with COVID-19 almost simultaneously. They are treated in different hospitals, and where colchicine is administered in high doses, the patient recovered. The other patient developed complications and died on standard treatment without high doses of colchicine. An outpatient accidentally overdosed on colchicine (12.5mg). The therapy was stopped immediately. Clinically, on the third day, there are absolutely no symptoms. These cases reaffirm the prophylactic effect of BRH and the curative effect of high-dose colchicine